Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

NEXT STORY
Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
PREV STORY
Brain Scientific Updates Disposable EEG Headset Sales Plan, Supply Scale-Up, and IP Status
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

II-VI Incorporated Launches Ultraviolet Fluorescence Filters for Biomedical Instruments  

PITTSBURGH, Jan. 17, 2018 (GLOBE NEWSWIRE) -- II‐VI Incorporated (NASDAQ:IIVI), a leading provider of ...

author_avatar
NASDAQ Market News

US Department of Defense Research Collaboration Moves Forward

Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned ...

author_avatar
NASDAQ Market News

Agios Announces Chief Executive Officer Succession Plan

- David Schenkein, M.D., Agios Long-Time Chief Executive Officer, to Become Executive Chairman, Effective ...

author_avatar
NASDAQ Market News